Navigation Links
Simons Foundation awards Emory scientists $3M for autism gene research
Date:10/4/2007

The Simons Foundation has awarded scientists at Emory University School of Medicine a three-year grant of more than $3 million to uncover genes on the X chromosome that may contribute to the development of autism.

Stephen T. Warren, PhD, chair of the Emory Department of Human Genetics, is principal investigator of the program project that also includes Michael Zwick, PhD, and Brad Coffee, PhD, both Emory faculty members in human genetics.

Autism occurs four to nine times more frequently in males than in females, and genes on the X chromosome have long been suspected as being responsible for this male predilection. However, the ability to comprehensively examine the entire X chromosome for abnormalities has not been technically feasible until now.

Using technologies recently developed in the Department of Human Genetics, the Emory scientists will carry out a comprehensive search for genetic abnormalities of the X chromosome in 330 patients with autism.

The first project will scan the entire length of the X chromosome for subtle deletions or duplications using high-resolution microarrays containing short DNA fragments that can interrogate 2.1 million sites on the X chromosome. The second project will sequence all of the 1,098 genes on the X chromosome using a "next generation" DNA sequencing instrument. The final project will scan the entire X chromosome for evidence of "epigenetic" abnormalities, which are due to differences in gene expression rather than changes in the DNA itself.

This exhaustive survey of the human X chromosome should identify X-linked variation for autism susceptibility if such variation exists, says Dr. Warren.

"The unique genomic technologies available at Emory allow studies that would have been incomprehensible only a few years ago and will enable us to examine the 155 million bases of the X chromosome in minute detail in patients with autism," he explains.

Finding a predisposing gene is considered the most important first step to uncovering the true basis of a disease and to developing diagnostic tests and therapeutic approaches.


'/>"/>

Contact: Holly Korschun
hkorsch@emory.edu
404-727-3990
Emory University
Source:Eurekalert

Related biology news :

1. W.M. Keck Foundation funds study of friendly microbes
2. Digging in the dirt for lifes biochemical foundations
3. Protein folding: Building a strong foundation
4. Emory Study Tests Bone Marrow Stem Cells to Improve Circulation in Legs
5. Researchers Uncover Key Step In Manufacture of Memory Protein
6. Emory Eye Center Implants Its First Retinal Chips In Patients With Retinitis Pigmentosa
7. Nanogen Issued Patent for Electronic Microarray With Memory
8. Rats infected as newborns grew up vulnerable to memory problems during an immune challenge
9. Structure-building cell signals also may influence learning and memory
10. Mice brains shrink during winter, impairing some learning and memory
11. Montreal researchers probe the genetic basis of memory
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/31/2017)...  Spero Therapeutics, LLC, a biopharmaceutical company founded ... bacterial infections, today announced it has acquired a ... Bono Bio Ltd (PBB) to bolster its pipeline ... of Gram-negative bacteria.   The assets acquired have been ... group company. "The acquisition of these ...
(Date:1/25/2017)... , Jan. 25, 2017 The Elements of ... (IAM) lifecycle is comprised of a comprehensive set ... purpose of maintaining digital identities and providing a ... applications. There are significant number of programs opted ... to time by optimizing processes and changing policies. ...
(Date:1/21/2017)... , Jan 20, 2017 Research and Markets ... Market 2017-2021" report to their offering. ... The global voice recognition biometrics market ... The report covers the present scenario and the ... To calculate the market size, the report considers the revenue generated ...
Breaking Biology News(10 mins):
(Date:2/28/2017)... ... February 28, 2017 , ... ... antibody therapeutics from millions-diverse immune repertoires, today announced a strategic partnership with ... genetically engineered to express human antibodies. The partnership will use GigaGen technology to ...
(Date:2/28/2017)... 2017  ITL Limited ( ASX:ITD ), an ... partner that provides innovative products and solutions to ... announces its rebrand to ITL Health Group (ITL). ... of the Company,s unified global rebranding plan and ... corporate website, ITLHealthGroup.com . ITL,s new brand ...
(Date:2/28/2017)... and NEW YORK , February 28, ... Application accepted by the FDA for avelumab  Prognosis ... has metastasized   EMD ... Germany , in the US and Canada ... Food and Drug Administration (FDA) has accepted for Priority Review ...
(Date:2/27/2017)... A Europe-wide survey of institutes conducted by the Basel Declaration ... treat them with due care. The survey polled a total of ... indicates that there is a strong commitment among animal researchers across ... of the 3Rs (Refine, Reduce, Replace)  ... What are the 3Rs? Refine: ...
Breaking Biology Technology: